Verrica Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference and the RBC Capital Markets Global Healthcare Conference
Verrica Pharmaceuticals (Nasdaq: VRCA) announced that CEO Ted White will present at two virtual healthcare conferences: the Bank of America Merrill Lynch Global Healthcare Conference on May 12, 2020, from 4:20 PM to 4:50 PM ET, and the RBC Capital Markets Global Healthcare Conference on May 19, 2020, from 4:50 PM to 5:15 PM ET. The presentations will be accessible via live webcasts on the company’s Investors page. Currently, Verrica is developing VP-102, a potential therapy for viral skin diseases, with an FDA decision slated for July 13, 2020.
- None.
- None.
Insights
Analyzing...
WEST CHESTER, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will virtually present at two upcoming virtual healthcare conferences. Details for each presentation are included below:
Bank of America Merrill Lynch Global Healthcare Conference
Tuesday, May 12th
4:20 PM – 4:50 PM ET
RBC Capital Markets Global Healthcare Conference
Tuesday, May 19th
4:50PM – 5:15 PM ET
Live webcasts of the presentations can be accessed at the company’s Investors page under Events and Presentations at https://investors.verrica.com/events-and-presentations. Webcast replays will also be available on this website shortly after conclusion of the event for 30 days.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions. The Company’s late-stage product candidate, VP-102, is a potential first-in-class topical therapy for the treatment of molluscum contagiosum and common warts. Molluscum is a highly contagious viral skin infection affecting approximately six million people, primarily children, in the United States, and common warts are contagious skin growths affecting 22 million people. There are currently no FDA-approved treatments for molluscum or common warts. Following positive topline results from two pivotal Phase 3 trials, the Company submitted an NDA on September 13, 2019 for VP-102 for the treatment of molluscum; on November 26, 2019, the Company received notice that the FDA accepted the NDA for filing, with a Prescription Drug User Fee Act (PDUFA) goal date of July 13, 2020. If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name YCANTH™. Verrica has completed a Phase 2 clinical trial clinical trial of VP-102 for the treatment of verruca vulgaris, or common warts and, in light of the COVID-19 pandemic, intends to launch two Phase 3 clinical trials when conditions are appropriate. VP-102 is also currently in a Phase 2 trial for the treatment of external genital warts. The Company is conducting necessary preclinical activities for VP-103, its second cantharidin-based product candidate, and, in light of the COVID-19 pandemic, intends to launch a Phase 2 clinical trial in subjects with plantar warts when conditions are appropriate. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com
Chiara Russo
Solebury Trout
617.221.9197
crusso@troutgroup.com
Media:
Joshua R. Mansbach
Solebury Trout
646-378-2964
jmansbach@troutgroup.com
FAQ
What are the dates and times for Verrica Pharmaceuticals' virtual presentations?
How can I access the webcasts of the presentations by Verrica Pharmaceuticals?
What is the FDA decision date for Verrica Pharmaceuticals' VP-102?
What conditions does VP-102 aim to treat?
Is there an FDA-approved treatment for molluscum contagiosum?
